Recombinant Mouse Interferon Beta 1, Fibroblast

• Cat.No.: Ifnb1-684M
• Product Overview: Recombinant MouseIfnb1 was expressed in E.coli.

Specification

• Cat. No.: Ifnb1-684M
• Description: Ifnb1 is aprotein that in humans is encoded by the Ifnb1 gene.
• Source: E. coli
• Species: Mouse
• Form: Liquid in PBS,carrier free.
• Molecular Weight: 19.6 kDa
• Concentration: 1 x 106units/ml
• Purity: > 95%
• Endotoxin Level: < 0.1 EU/μg Ifnb1.
• Purification: Combinationof ion exchange, hydrophobic interaction, and size exclusion chromatography.
• Specific Activity: Ifnb1 wastitrated with the use of the cytopathic effect inhibition assay. Units of activitywere measured on mouse L929 cells with encephalomyocarditis virus (EMCV); in thisassay, the EC50 for Ifnb1 is ~ 2.5 U/ml. Theactivity was determined relative to a labstandard of mouse Ifnb1 which was calibrated to the NIH Mouse Ifnb1 standard.
• Storage: Store inworking aliquots at -80°C. Further dilutions should be made in bufferscontainingproteinsuch as 0.1% BSA. Please note that the addition of any carrier proteinintothisproduct may produce unwanted endotoxin. This depends upon the particular applicationemployed. Avoid repeated freeze-thaw cycles.
• OfficialSymbol: Ifnb1

Gene Information

• Gene Name: Ifnb1 interferon beta 1,fibroblast [ Mus musculus ]
• Synonyms: Ifnb1; interferonbeta 1, fibroblast; Ifb; IFNB; IFN-beta; interferon beta; OTTMUSP00000008111
• Gene ID: 15977
• mRNA Refseq: NM_010510
• Protein Refseq: NP_034640
• Chromosome Location: 4 C4; 442.6 cM
• Pathway: Chagas disease(American trypanosomiasis); Cytokine-cytokine receptor interaction; Cytokinesand Inflammatory Response (BioCarta); Cytosolic DNA-sensing pathway;Hepatitis C; Herpes simplex infection; Influenza A; Jak-STAT signalingpathway; Measles; Natural killer cell mediated cytotoxicity; Osteoclast;Osteoclast differentiation; RIG-I-like receptor signaling pathway; Senescenceand Autophagy; Toll-like receptor signaling pathway; Tuberculosis; Type IIinterferon signaling (IFNG)
• Function: cytokine activity;cytokine receptor binding; transcription corepressor activity

Reviews

06/24/2021

The manufacturer not only ensures the provision of superior protein but also aids researchers with their solid technical support, offering the necessary resources to optimize experimental protocols.

08/29/2020

the IFNB1 protein offers numerous advantages for researchers conducting trials due to its high quality and stability.

11/08/2018

manufacturers or suppliers of proteins can play a crucial role in supporting researchers during trials.

Q&As

Are there any contraindications for IFNB1 treatment?

IFNB1 is generally not recommended for individuals with a history of hypersensitivity to interferons or other components of the drug. It should be used with caution in patients with certain pre-existing medical conditions.

Can IFNB1 be used in cancer treatment?

IFNB1 is being investigated for its potential role in cancer treatment due to its immunomodulatory effects. Clinical trials are ongoing to evaluate its efficacy in various types of cancer.

What are the potential side effects of IFNB1 treatment?

Common side effects include flu-like symptoms, injection site reactions, and changes in blood cell counts. Serious side effects are rare but can include liver problems and allergic reactions.

How is IFNB1 administered in clinical settings?

IFNB1 is often administered through subcutaneous or intramuscular injections. The frequency and dosage depend on the specific condition being treated.

In what other conditions is IFNB1 protein clinically utilized?

IFNB1 is also used in the treatment of certain viral infections, such as hepatitis B and C. It has antiviral properties that can inhibit viral replication.